Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer 2021-03-16 15:00
New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines 2021-02-25 21:00
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations 2020-11-27 08:42
Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics 2020-11-09 21:00
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis 2020-10-06 20:00
Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 2020-09-14 10:41
New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety 2020-09-11 20:00
Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis 2020-09-10 20:00
Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis 2020-09-03 20:00
Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS 2020-05-28 16:00
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020 2020-05-14 06:46
Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care 2020-04-30 20:00
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) 2020-03-02 15:02
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma 2019-10-29 02:00
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019 2019-09-27 14:00
New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care 2019-09-23 14:00
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma 2019-09-20 20:34
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations 2019-09-11 14:30
Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019 2019-09-09 20:00
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations 2019-06-04 02:16
1